However, these current therapies used to treat patients with NRAS‐mutant melanoma are not very efficient, owing to the aggressive nature of tumor cells and complex changes in molecular signaling (Johnson & Puzanov, 2015). The gene discussed is NRAS; the disease is neoplasm.